Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer

Semiglazova, Tatiana Yurievna; Osipov, Mikhail A.; Krivorotko, Petr; Protsenko, S.A. Protsenko; Семиглазов, В. В.; Donskih, Roman; Клименко, В. В.; Tsirlina, E.; Berstein, Lev M.; Anisimov, Vladimir N.; Belyaеv, Alexey M.

doi:10.1093/annonc/mdz241.002

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, some promising evidence has been reported, such as the finding that topical melatonin counteracts the effects of radiotherapy in breast cancer patients [ 42 ]. To date, only eight RCTs have studied melatonin in this regard [ 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. Among them, six tested melatonin at doses ranging from 10 to 20 mg/day and two at 3 mg/day.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

The purpose of this systematic review is to provide an overview of the existing knowledge on the therapeutic potential of melatonin to counteract the undesirable effects of chemotherapy in breast cancer patients. To this aim, we summarized and critically reviewed preclinical- and clinical-related evidence according to the PRISMA guidelines. Additionally, we developed an extrapolation of melatonin doses in animal studies to the human equivalent doses (HEDs) for randomized clinical trials (RCTs) with breast cancer patients. For the revision, 341 primary records were screened, which were reduced to 8 selected RCTs that met the inclusion criteria. We assembled the evidence drawn from these studies by analyzing the remaining gaps and treatment efficacy and suggested future translational research and clinical trials. Overall, the selected RCTs allow us to conclude that melatonin combined with standard chemotherapy lines would derive, at least, a better quality of life for breast cancer patients. Moreover, regular doses of 20 mg/day seemed to increase partial response and 1-year survival rates. Accordingly, this systematic review leads us to draw attention to the need for more RCTs to provide a comprehensive view of the promising actions of melatonin in breast cancer and, given the safety profile of this molecule, adequate translational doses should be established in further RCTs.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…На моделях перевиваемых опухолей молочной железы впервые был оценен эффект совместного применения метформина и/или мелатонина с доксорубицином, паклитакселом и торемифеном [94]. Полученные данные послужили обоснованием для проспективных рандомизированных клинических исследований, в которых в зависимости от биологического подтипа было изучено влияние мелатонина и метформина в комбинации с предоперационной лекарственной терапией (гормонотерапией торемифеном при эстроген-рецептор-позитивных опухолях или антрациклин-и таксансодержащей химиотерапией) на частоту объективных ответов, степень патоморфологического ответа и уровень пролиферативной активности опухоли [71,95,96]. В 2015-2017 гг.…”

Section: лечение и реабилитацияunclassified

Three pandemics at once: Noninfectious (cancer), infectious (COVID-19), and behavioral (hypokinesia)

Golubev¹,

Semiglazova²,

Klyuge³

et al. 2021

Problems in oncology

View full text Add to dashboard Cite

The narrative review addresses the evidence that physical activity can improve the results of prevention and treatment and of the conditions that feature increased risks of their development with aging. The main attention is paid to cancer and problems arising because of physical activity limitations associated with COVID-19 pandemic. To promote physical activity, which is known to reduce the risks of COVID-19 complications and of cancer, it is important to help patients and physicians in understanding the reasons why physical activity can be beneficial, more than the pharmacological means thought to reproduce some of its effects, in cancer prevention and treatment upon all differences between the locations of tumors and the pathways of carcinogenesis. Therefore, the physiological and molecular mechanisms behind the usefulness of physical activity in oncology are discussed. Based on this discussion, data on quantitative relationships between oncological risks, physical activity, and the use of its alleged pharmacological mimetics are addressed.

show abstract

Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma

Novik

Protsenko²,

Балдуева³

et al. 2021

The Oncologist

View full text Add to dashboard Cite

show abstract

Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer

Cited by 6 publications

References 0 publications

Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

Three pandemics at once: Noninfectious (cancer), infectious (COVID-19), and behavioral (hypokinesia)

Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma

Contact Info

Product

Resources

About